If you have been reading about obesity research and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-05. Numbers and descriptions here follow the published literature rather than marketing material.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Work by scientists such as Anton Yuryev has contributed to understanding mitochondrial-associated proteins and their interactions. During his postdoctoral research, Yuryev demonstrated that the A-RAF kinase, a signaling protein, can localize to mitochondria, providing insight into how cellular signaling pathways intersect with mitochondrial function. His broader work in molecular biology and bioinformatics has also explored gene regulation, protein interactions, and biological networks, helping to contextualize mitochondrial processes within larger cellular systems.
In 1987, Tengku Razaleigh Hamzah, who had been demoted from Finance Minister to Trade and Industry Minister, challenged Mahathir for UMNO's presidency, and effectively the prime ministership. Razaleigh's bid was supported by Musa, who had resigned as deputy prime minister the previous year. While once close allies with Mahathir, both fell out with Musa claiming that Mahathir no longer trusted him. Razaleigh and Musa ran for the UMNO presidency and deputy presidency on a joint ticket against Mahathir and his new choice for deputy Abdul Ghafar Baba. Mahathir's Team A enjoyed the press's support, most party heavyweights, and even Iskandar, now the Agong. However, other prominent figures such as Abdullah Ahmad Badawi supported Team B. In the election, held on 24 April 1987, Team A prevailed. Mahathir was re-elected by a narrow margin, receiving the votes of 761 party delegates to Razaleigh's 718. Ghafar defeated Musa by a slightly larger margin. Mahathir responded by purging seven Team B supporters from his ministry. At the same time, Team B refused to accept defeat and initiated litigation. In an unexpected decision in February 1988, the High Courts ruled that UMNO was an illegal organisation as some of its branches had not been lawfully registered. Each faction raced to register a new party under the UMNO name. Mahathir's side successfully registered the name "UMNO Baru" ("new UMNO"), while Team B's application to register "UMNO Malaysia" was rejected. Nevertheless, UMNO Malaysia registered the party as Semangat 46 instead under Tengku Razaleigh Hamzah's leadership.
Hair analysis to detect addictive substances has been used by court systems in the United States, United Kingdom, Canada, and other countries worldwide. In the United States, hair testing has been accepted in court cases as forensic evidence following the Frye Rule, the Federal Rules of Evidence, and the Daubert Rule. As such, hair testing results are legally and scientifically recognized as admissible evidence. Hair testing is commonly used in the USA as pre-employment drug test. The detection time for this test is roughly 3 months, which is the time, that takes head hair to grow ca. 1.5 inches, that are collected as a specimen. Longer detection times are possible with longer hair samples. A 2014 collaborative US study of 359 adults with moderate-risk drug use found, that a large number of participants, who reported drug use in the last 3 months, had negative hair tests. The tests were done using an immunoassay followed by a confirmatory GC-MS. For marijuana, only about half of self-disclosed users had a positive hair test. Under-identification of drug use by hair testing (or over-reporting) was also widespread for cocaine, amphetamines, and opioids. Because such under-identification was more common among participants, who self-reported an infrequent use, the authors suggested, that the immunoassay did not have the sensitivity required for such infrequent uses. It is worth noting, that most earlier studies reported, that hair tests found ca. 50-fold higher prevalence of illicit drug use, than self reports.
== Therapeutics targeting nonsense mutation diseases == Therapeutics for diseases caused by nonsense mutations attempt to recapitulate wild-type function by decreasing the efficacy of NMD, facilitating readthrough of the premature stop codon during translation, or editing the genomic nonsense mutation. Antisense oligonucleotides to suppress the expression of NMD and translation termination proteins are being explored in animal models of nonsense mutation-induced disease. Other RNA therapeutics under investigation include synthetic suppressor tRNAs that enable ribosomes to insert an amino acid, instead of initiating chain termination, upon encountering premature stop codons. CRISPR-Cas9 based single nucleotide substitutions have been used to generate amino acid codons from stop codons, achieving an editing success rate of 10% in cell cultures. Read-through has been achieved using small molecule drugs such as aminoglycosides and negamycin. An oxadiazole, ataluren (previously PTC124), facilitates the selective read-through of aberrant stop codons, rendering it a potential therapeutic against nonsense mutation-induced disease. Ataluren, sold under the tradename Translarna, is currently an approved treatment for Duchenne muscular dystrophy in the European Economic area and Brazil. However, phase III trials of Ataluren as a cystic fibrosis therapeutic have failed to meet their primary endpoints.
Troika, unable to obtain further funding from Activision or other publishers, released its employees in two waves: the first in November 2004, followed by the remaining staff in December, except for its three founders, Anderson, Boyarsky, and Tim Cain. Some employees worked without pay to fix the game. When the company closed in February 2005, it had secured no other game development deals. That month, Boyarsky confirmed that Troika had not been working on a patch for the game since most of its staff had been gone since December 2004. In a 2006 interview, Anderson said that although Troika Games's library had been critically well received, consistent technical issues had marred the perception of the company's games, contributing to Troika's difficulty in obtaining new projects. In 2013, Mitsoda said that Bloodlines was released at "the worst possible time - most people didn't even know we were out ... fans and the Troika [developers] are always going to wonder what the game could have been like with another six months." In a 2017 interview, Boyarsky echoed Mitsoda's sentiments, saying that a further three to six months of development time could have allowed Troika to address many technical flaws, but he was unsure that they could have resolved larger issues. He said, "I feel the second half of the game isn't as good as the first. I feel like we devolved into relying too much on combat at the end." Boyarsky noted that it was impossible to know if the fixes would have made Bloodlines more successful or if it would have remained a niche product.
Sources: en.wikipedia.org
=== Diagnostic uses === Because of the carcinogenicity of its beta radiation in the thyroid in small doses, I-131 is rarely used primarily or solely for diagnosis (although in the past this was more common due to this isotope's relative ease of production and low expense). Instead the more purely gamma-emitting radioiodine iodine-123 is used in diagnostic testing (nuclear medicine scan of the thyroid). The longer half-lived iodine-125 is also occasionally used when a longer half-life radioiodine is needed for diagnosis, and in brachytherapy treatment (isotope confined in small seed-like metal capsules), where the low-energy gamma radiation without a beta component makes iodine-125 useful. The other radioisotopes of iodine are never used in brachytherapy. The use of 131I as a medical isotope has been blamed for a routine shipment of biosolids being rejected from crossing the Canada—U.S. border. Such material can enter the sewers directly from the medical facilities, or by being excreted by patients after a treatment.
== Top scorers == Following the conclusion of the competition, Wrexham player Paul Mullin was awarded the FA Cup Golden Ball Award, commemorating him as the top scorer of the season from the extra preliminary round through to the final with eight goals.
=== Leukemia === James has also researched children diagnosed with leukemia in Fallon, Nevada. She originally received a grant from the United States Environmental Protection Agency to conduct this research in 2004 and presented preliminary results the following year. James speculated that the Fallon children had a metabolic predisposition to develop leukemia when exposed to environmental contaminants. She never published her final results, because she only had 20 blood samples--"not enough to reach a conclusive result."
=== Reaction === Limulus clotting enzyme uses 2H2O to cleave the Arg18-Gly19 and Arg46-Thr47 linkages in coagulogen, forming coagulin + two peptide products. This process activates coagulin, allowing it to gel and form clots around bacterial invaders. The reaction is hydrolytic and catalyzed by the His-Asp-Ser triad in the active site. The hydroxyl group in serine acts as a nucleophile, attacking the carbonyl carbon in the peptide bond. Histidine’s nitrogen atom accepts the hydrogen from serine’s hydroxyl group to make serine a stronger nucleophile. Aspartic acid forms hydrogen bonds with histidine to make this nitrogen atom more electronegative and therefore more likely to accept the hydrogen. The nucleophilic attack results in the peptide bond breaking, allowing one peptide fragment to be released. A water molecule is then deprotonated by the histidine. The resulting hydroxyl acts as a nucleophile to break the bond between the serine and the carbonyl, releasing the rest of the protein. The process is then repeated at the other peptide bond.
==== Inaccurate labeling ==== Marketing classifications often do not correspond to taxonomic ones. The "Ambersweet" cultivar is marketed and sold as an orange, but does not descend from the same common ancestor as sweet oranges; it has grapefruit, orange, and mandarin ancestry. Fruits are often sold as mandarin, tangerine, or satsuma (which may be synonyms). Many fruits sold under these names such as Sunbursts and Murcotts are hybrids with grapefruit ancestry.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.